Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01101009|
Recruitment Status : Completed
First Posted : April 9, 2010
Last Update Posted : January 15, 2013
Daiichi Sankyo Europe, GmbH
Information provided by (Responsible Party):
Daiichi Sankyo, Inc. ( Daiichi Sankyo Europe, GmbH )
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||December 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Ruilope L, Schaefer A. The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther. 2013 Dec;30(12):1086-99. doi: 10.1007/s12325-013-0076-6. Epub 2013 Nov 30. Erratum in: Adv Ther. 2015 Feb;32(2):184-5. Adv Ther. 2014 Apr;31(4):472. Adv Ther. 2014 Feb;31(2):243.
Ruilope LM, Schaefer A. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study. Contemp Clin Trials. 2011 Sep;32(5):710-6. doi: 10.1016/j.cct.2011.04.011. Epub 2011 May 14.